Cargando…

Daylight-Mediated, Passive, and Sustained Release of the Glaucoma Drug Timolol from a Contact Lens

[Image: see text] Timolol, a potent inhibitor of β-adrenergic receptors (βARs), is a first-line drug for decreasing the intraocular pressure (IOP) of patients with glaucoma. Timolol is administered using 0.5% eye-drop solutions at >3 × 10(7) times the inhibitory concentration (k(i)) for βARs. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mu, Changhua, Shi, Meng, Liu, Ping, Chen, Lu, Marriott, Gerard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2018
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311683/ https://www.ncbi.nlm.nih.gov/pubmed/30648151 http://dx.doi.org/10.1021/acscentsci.8b00641

Ejemplares similares

Patient perspectives when switching from Cosopt(®) (dorzolamide-timolol) to Azarga™ (brinzolamide-timolol) for glaucoma requiring multiple drug therapy
por: Auger, Graham Anthony, et al.
Publicado: (2012)

Comparison of Latanoprost/Timolol with Carbonic Anhydrase Inhibitor and Dorzolamide/Timolol with Prostaglandin Analog in the Treatment of Glaucoma
por: Inoue, Kenji, et al.
Publicado: (2014)

Daylight Science and Daylighting Technology
por: Kittler, Richard, et al.
Publicado: (2012)

Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension
por: Teus, Miguel A, et al.
Publicado: (2009)

Effect of dorzolamide/timolol combination on the visual field in glaucoma
por: Takeda, Sakurako, et al.
Publicado: (2014)

A comparative study on the efficacy, safety, and cost-effectiveness of bimatoprost/timolol and dorzolamide/timolol combinations in glaucoma patients
por: Jothi, R., et al.
Publicado: (2010)

Development and evaluation of polycaprolactone-based electrospun nanofibers containing timolol maleate as a sustained-release device for treatment of glaucoma: in vivo evaluation in equine eye
por: Mirzaeei, Shahla, et al.
Publicado: (2022)

Safety and efficacy of fixed-combination travoprost/timolol in patients with open-angle glaucoma or ocular hypertension not controlled with timolol monotherapy
por: Jordão, Marcelo Lopes da Silva, et al.
Publicado: (2014)

Efficacy and safety of brinzolamide/timolol fixed combination compared with timolol in Japanese patients with open-angle glaucoma or ocular hypertension
por: Yoshikawa, Keiji, et al.
Publicado: (2014)

Formulation and In-vitro Characterization of Sustained Release Matrix Type Ocular Timolol Maleate Mini-Tablet
por: Mortazavi, Seyed Alireza, et al.
Publicado: (2014)

Treatment persistence and cost-effectiveness of latanoprost/latanoprost–timolol, bimatoprost/bimatoprost–timolol, and travoprost/travoprost–timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
por: Lafuma, Antoine, et al.
Publicado: (2011)

Preference for a fixed combination of brinzolamide/timolol versus dorzolamide/timolol among patients with open-angle glaucoma or ocular hypertension
por: Sanseau, Ana, et al.
Publicado: (2013)

Efficacy and safety of brinzolamide/timolol fixed combination compared with timolol in Japanese patients with open-angle glaucoma or ocular hypertension [Erratum]
Publicado: (2014)

Cyclodextrin-containing hydrogels as an intraocular lens for sustained drug release
por: Li, Xiao, et al.
Publicado: (2017)

The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies
por: Radcliffe, Nathan M
Publicado: (2014)

Measuring Daylight: A Review of Dosimetry in Daylight Photodynamic Therapy
por: O’Mahoney, Paul, et al.
Publicado: (2019)

Simple mathematical models to link climate-based daylight metrics with daylight factor metrics and daylighting design implications
por: Li, Shuyang, et al.
Publicado: (2023)

Layer-by-layer coated silicone-based soft contact lens hydrogel for diclofenac sustained release
por: Silva, Diana, et al.
Publicado: (2021)

Brinzolamide 1%/timolol versus dorzolamide 2%/timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study
por: Altafini, Romeo, et al.
Publicado: (2015)

Contact Lenses Delivering Nitric Oxide under Daylight for Reduction of Bacterial Contamination
por: Seggio, Mimimorena, et al.
Publicado: (2019)

Stimulus-Responsive Contact Lens for IOP Measurement or Temperature-Triggered Drug Release
por: Lee, Se-Hee, et al.
Publicado: (2020)

Evolution of self-sustained circadian rhythms is facilitated by seasonal change of daylight
por: Seki, Motohide, et al.
Publicado: (2022)

Efficacy, safety and tolerability of combination therapy with timolol and dorzolamide in glaucoma and ocular hypertension
por: Ichhpujani, Parul, et al.
Publicado: (2010)

Evaluation of brimonidine-timolol fixed combination in patients of primary open-angle glaucoma
por: Joshi, Sachin R, et al.
Publicado: (2013)

The Effect of Rebamipide on Ocular Surface Disorders Induced by Latanoprost and Timolol in Glaucoma Patients
por: Tokuda, Naoto, et al.
Publicado: (2015)

Efficacy and Tolerability of Fixed-Combination Brinzolamide/Timolol in Latin American Patients with Open-Angle Glaucoma or Ocular Hypertension Previously on Brimonidine/Timolol Fixed Combination
por: Alezzandrini, Arturo, et al.
Publicado: (2014)

THE CHEMISTRY OF DAYLIGHT VISION
por: Bliss, Alfred Frederick
Publicado: (1946)

Sustained Release of a Polymeric Wetting Agent from a Silicone-Hydrogel Contact Lens Material
por: Zheng, Ying, et al.
Publicado: (2022)

Rational use of the fixed combination of dorzolamide – timolol in the management of raised intraocular pressure and glaucoma
por: Yeh, Jason, et al.
Publicado: (2008)

Formulation and evaluation of stimuli-sensitive hydrogels of timolol maleate and brimonidine tartrate for the treatment of glaucoma
por: Dubey, Akhilesh, et al.
Publicado: (2014)

Polymeric ocular hydrogels and ophthalmic inserts for controlled release of timolol maleate
por: Singh, Vinod, et al.
Publicado: (2011)

‘The Waste of Daylight’: Rhythmicity, Workers’ Health and Britain’s Edwardian Daylight Saving Time Bills
por: Hussey, Kristin D
Publicado: (2021)

A patient preference comparison of Azarga(™) (brinzolamide/timolol fixed combination) vs Cosopt(®) (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension
por: Mundorf, Thomas K, et al.
Publicado: (2008)

Additive effects and safety of fixed combination therapy with 1% brinzolamide and 0.5% timolol versus 1% dorzolamide and 0.5% timolol in prostaglandin‐treated glaucoma patients
por: Aihara, Makoto, et al.
Publicado: (2017)

Commentary: Contact lens sensor-measured circadian intraocular pressure and glaucoma progression
por: Krishnadas, R
Publicado: (2020)

Wireless theranostic smart contact lens for monitoring and control of intraocular pressure in glaucoma
por: Kim, Tae Yeon, et al.
Publicado: (2022)

Daylight Photodynamic Therapy: An Update
por: Lee, Chaw-Ning, et al.
Publicado: (2020)

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
por: Gheith, Moataz E, et al.
Publicado: (2008)

Bradycardia From a Non-selective Beta-Adrenergic Antagonist, Timolol, Applied Ophthalmologically for Glaucoma
por: May, Gedaliah, et al.
Publicado: (2022)

Daylight Photoactive TiO(2) Sol-Gel Nanoparticles: Sustainable Environmental Contribution
por: Barcelos, Daniel Alves, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s3b40mi9qudrlo5f19pd5a38rb